Business
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 millionQ1 2026 fully diluted GAAP EPS of $0.05, non-GAAP fully diluted EPS of $0.14, and Adjusted EBITDA of $5.7 millionReceived FDA approval for and launched DESMODA™Acquired and relaunched HEMANGEOL®Announced initiation of ET-700 clinical study, the Company’s extended-release formulation of zinc acetat
About this update from Eton Pharmaceuticals, Inc.
[{"type":"image","alt":"Eton Pharmaceuticals","displaySize":"","headline":null,"caption":"Eton Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wcuthC_koftYVXvofM_o3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340","width":300,"height":86},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/wcuthC_koftYVXvofM_o3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Q1 2026 fully diluted GAAP EPS of $0.05, non-GAAP fully diluted EPS of $0.14, and Adjusted EBITDA of $5.7 million","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Received FDA approval for and launched DESMODA™","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Acquired and relaunched HEMANGEOL®","length":34,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced initiation of ET-700 clinical study, the Company’s extended-release formulation of zinc acetate","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Received FDA clearance to proceed on INCRELEX® label harmonization study","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Management to hold conference call today at 4:30pm ET","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":651,"olType":false},{"type":"text","content":"DEER PARK, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2026.","length":297,"tagName":"p"},{"type":"text","content":"“With re...